Neuren Pharmaceuticals Ltd - Asset Resilience Ratio

Latest as of June 2025: 90.43%

Neuren Pharmaceuticals Ltd (NEU) has an Asset Resilience Ratio of 90.43% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Neuren Pharmaceuticals Ltd (NEU) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

AU$299.54 Million

≈ $211.94 Million USD Cash + Short-term Investments

Total Assets

AU$331.25 Million

≈ $234.38 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Neuren Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Neuren Pharmaceuticals Ltd's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Neuren Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore NEU strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$5.91 Million	1.78%
Short-term Investments	AU$293.63 Million	88.64%
Total Liquid Assets	AU$299.54 Million	90.43%

Asset Resilience Insights

Very High Liquidity: Neuren Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 90.43% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Neuren Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Neuren Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Genscript Biotech Corporation F:G51	Biotechnology	13.79%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
89bio Inc NASDAQ:ETNB	Biotechnology	71.60%
Pacific Shuanglin Bio pharmacy Co Ltd SHE:000403	Biotechnology	2.66%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	74.48%

Annual Asset Resilience Ratio for Neuren Pharmaceuticals Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Neuren Pharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	53.47%	AU$219.09 Million ≈ $155.02 Million	AU$409.71 Million ≈ $289.89 Million	-31.80pp
2023-12-31	85.27%	AU$211.44 Million ≈ $149.61 Million	AU$247.97 Million ≈ $175.45 Million	-2.27pp
2022-12-31	87.54%	AU$37.88 Million ≈ $26.80 Million	AU$43.27 Million ≈ $30.61 Million	+12.97pp
2021-12-31	74.57%	AU$29.87 Million ≈ $21.14 Million	AU$40.06 Million ≈ $28.34 Million	+66.61pp
2018-12-31	7.96%	AU$2.12 Million ≈ $1.50 Million	AU$26.64 Million ≈ $18.85 Million	-51.60pp
2017-12-31	59.56%	AU$10.69 Million ≈ $7.56 Million	AU$17.94 Million ≈ $12.70 Million	+22.98pp
2016-12-31	36.59%	AU$2.27 Million ≈ $1.61 Million	AU$6.21 Million ≈ $4.39 Million	--

pp = percentage points

About Neuren Pharmaceuticals Ltd

AU:NEU Australia Biotechnology

Market Cap

$1.85 Billion

AU$2.62 Billion AUD

Market Cap Rank

#6811 Global

#161 in Australia

Share Price

AU$20.68

Change (1 day)

+0.68%

52-Week Range

AU$11.28 - AU$23.64

All Time High

AU$25.11